RetinalGenix Technologies (RTGN) Common Equity (2020 - 2026)

RetinalGenix Technologies (RTGN) has 7 years of Common Equity data on file, last reported at -$2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 53.37% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (down 53.37% YoY), and the FY2025 full-year result was -$2.3 million, down 57.43% from the prior year.
• Common Equity declined to -$2.6 million in Q1 2026, from -$2.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$675175.0 in Q2 2022 to a low of -$2.6 million in Q1 2026.
• A 5-year average of -$1.6 million and a median of -$1.5 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 1789.02% in 2022 and fell 1.17% in 2024, its largest moves.
• Tracing RTGN's Common Equity over 5 years: stood at -$1.1 million in 2022, then plunged by 31.48% to -$1.4 million in 2023, then decreased by 4.05% to -$1.5 million in 2024, then tumbled by 57.43% to -$2.3 million in 2025, then decreased by 11.09% to -$2.6 million in 2026.
• Business Quant data shows RTGN's Common Equity at -$2.6 million in Q1 2026, -$2.3 million in Q4 2025, and -$2.2 million in Q3 2025.